Life Science Partner works closely with the senior leaders, investors and Board members in recruiting the key senior executives to build early and growth stage medical device, biopharmaceutical and healthcare information technology companies. Our clients utilize our extensive network of senior leaders with the operational skills and public-company knowledge to lead growing companies.
Featured Press Release
Chief Executive Officer
Life Science Partner announces the recruitment of Pete Wehrly, a leader in the spine and orthobiologics industries, to lead Vivex Biomedical. Vivex is a regenerative medicine company that markets tissue technology products and cellular therapies to meet the therapeutic demand in the areas of spine, dental, sport medicine, and wound care. With the launch of its VIA Disc product, a paradigm-changing treatment for Degenerative Disc Disease (DDD), the company sought a seasoned Chief Executive to lead the company through its next stage of growth.
Wehrly will help lead the expansion of Vivex’s sales force and guide the company through continued growth. He is a strategic leader with a broad background in growth and operational efficiencies within public and private companies in the medical device industry. Prior to joining Vivex, Wehrly served as Chief Executive Officer with Synaptive Medical, where he led a global team launching the 2nd generation disruptive surgical robotic technology portfolio across North America, Western Europe, and Asia.
He was also Chief Executive at PQ Bypass, where he led a cross-functional team in gaining CE Mark for their Detour System, a technology designed to advance the treatment of long-segment peripheral artery disease, and approval to embark on their PMA trial in the US and Europe.
Previously, Wehrly served as Group President for Covidien where he turned around the Respiratory and Monitoring Solutions business and was later responsible for the Vascular Therapies business. Wehrly is a seasoned executive in the spine industry having led several divisions of Medtronic including Spinal and Biologics for 8 years. He played an integral role in their global market leadership positions and saw them grow from $500M to over $2.8B in compound annual growth rate.
Wehrly will play a pivotal role in helping Vivex Biomedical during its next stage of growth and development as they launch a new product in the biologics space, leveraging his expertise in the spine industry and his commercial and operational strengths to ensure continued growth and preparation for a future financing event.